Press Room (Product News) http://www.news.sanofi.us/ MediaRoom ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause http://www.news.sanofi.us/2018-11-11-ODYSSEY-OUTCOMES-investigators-highlight-at-AHA-that-Praluent-R-alirocumab-Injection-was-associated-with-fewer-deaths-from-any-cause * Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL Sun, 11 Nov 2018 08:15:00 -0500 http://www.news.sanofi.us/2018-11-11-ODYSSEY-OUTCOMES-investigators-highlight-at-AHA-that-Praluent-R-alirocumab-Injection-was-associated-with-fewer-deaths-from-any-cause New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial http://www.news.sanofi.us/2018-11-07-New-England-Journal-of-Medicine-publishes-positive-detailed-results-from-Praluent-R-alirocumab-Injection-cardiovascular-outcomes-trial * Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001) Wed, 07 Nov 2018 17:00:00 -0500 http://www.news.sanofi.us/2018-11-07-New-England-Journal-of-Medicine-publishes-positive-detailed-results-from-Praluent-R-alirocumab-Injection-cardiovascular-outcomes-trial FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis http://www.news.sanofi.us/2018-11-06-FDA-grants-priority-review-for-Dupixent-R-dupilumab-as-potential-treatment-for-adolescents-with-uncontrolled-moderate-to-severe-atopic-dermatitis Tue, 06 Nov 2018 08:00:00 -0500 http://www.news.sanofi.us/2018-11-06-FDA-grants-priority-review-for-Dupixent-R-dupilumab-as-potential-treatment-for-adolescents-with-uncontrolled-moderate-to-severe-atopic-dermatitis FDA grants priority review for Sanofi's dengue vaccine candidate http://www.news.sanofi.us/2018-10-30-FDA-grants-priority-review-for-Sanofis-dengue-vaccine-candidate Tue, 30 Oct 2018 17:12:00 -0400 http://www.news.sanofi.us/2018-10-30-FDA-grants-priority-review-for-Sanofis-dengue-vaccine-candidate FDA approves asthma indication for Dupixent® (dupilumab) http://www.news.sanofi.us/2018-10-19-FDA-approves-asthsma-indication-for-Dupixent-R-dupilumab -- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Fri, 19 Oct 2018 17:55:00 -0400 http://www.news.sanofi.us/2018-10-19-FDA-approves-asthsma-indication-for-Dupixent-R-dupilumab